Core 3: Communications, Administrations, Advocacy, and Project Management
Core 3: Communications, Administrations, Advocacy, and Project Management
批准号:
10628613
负责人:
LAURA J ESSERMAN
金额:
$26.66万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
未结题
起止时间:
2017-09-08 至 2028-06-30
关键词:
AchievementAdvocacyAdvocateBreast Cancer TreatmentBudgetsClinicalClinical Drug DevelopmentCollaborationsCommunicationElementsEnsureFriendsGenerationsGoalsHuman ResourcesIndividualInfrastructureLeadershipMagnetic Resonance ImagingMeasurableMeasuresMethodologyModificationOffice of Administrative ManagementOutcomeParticipantPatient-Focused OutcomesPatientsProgram Research Project GrantsProtocols documentationRegimenRegulatory PathwayReportingResearch PersonnelRoleScienceSequential TreatmentSpecific qualifier valueStructureSubgroupTrainingTranslatingTranslational ResearchWorkdesignimaging biomarkerimprovedmalignant breast neoplasmmeetingsmolecular markernext generationnoveloperationpersonalized medicineprogramsresponse biomarkerrestrainttimelinetooltreatment responsetreatment strategytrial designwebinarworking group
中文摘要
该方案项目包括四个综合项目,以开发和维护开发和维护基础设施
在I-SPY2.2试验中实施改进,采用早期升级/降级治疗并确定
在监管证据生成框架内优化患者结局的治疗策略。主要目标是
通信、行政、宣传和项目管理(CAAP)的核心是确保计划
通过提供项目管理、领导力、
向所有项目和核心提供行政支助;以及将宣传纳入面向病人的所有方面
计划项目中的项目和核心。
也许CAAP核心最关键的作用是协调项目和核心的活动和交付成果
由研究赞助商QLHC、其临床操作团队和I-SPY2试验工作组主席组成。While计划
项目人员、核心和项目的任务是制定和完善技术和方法进步
在I-SPY2.2中采用的持续改进方法中所要求的,试验的所有操作方面是
研究赞助商的责任。由CAAP核心推动的方案项目总体绩效指标和项目绩效指标的工作
通过定义技术标准,将变更整合到与赞助商代表一起的试验操作中
赞助商临床运营团队的要求、规格和交付内容。
在其他职责中,CAAP核心确保我们的患者权益倡导者在所有项目团队中都有代表,
核心团队和项目间协作,以便他们能够带来他们独特和重要的视角来帮助满足
I-SPY2.2的以患者为中心的任务。
具体目标1:组织、整合和提供所有项目和核心的行政管理
具体目标2:提供项目管理监督,以跟踪各个项目的里程碑和时间表
核心。
具体目标3:促进协作和传播信息
英文摘要
The Program Project encompasses four integrated projects to develop and maintain the infrastructure for developing and
implementing improvements in the I-SPY2.2 trial that employs early escalation/de-escalation of treatment and identifies
treatment strategies to optimize patient outcomes within a regulatory evidence generation framework. The primary aims
of the Communications, Administration, Advocacy, and Project management (CAAP) Core are to ensure program
integration, collaboration, patient acceptance, and regulatory compliance by providing project management, leadership,
and administrative support to all Projects and Cores; as well as the integration of advocacy in all patient-facing aspects of
the Projects and Core in the Program Project.
Perhaps the most critical role of the CAAP core is to coordinate the activities and deliverables of the projects and cores
with the study sponsor QLHC, its clinical operations team and the I-SPY2 trial working group chairs. While program
project personnel, cores and projects are tasked with developing and refining the technical and methodological advances
required in the continuous improvement approach employed in I-SPY2.2, all operational aspects of the trial are the
responsibility of the study sponsor. The Program Project overall PIs and project PIs, facilitated by the CAAP core, work
to integrate the changes into the operations of the trial with sponsor representatives by defining the technical
requirements, specifications, and deliverables for the sponsor’s clinical operations team.
Among its other responsibilities, the CAAP Core ensures that our patient advocates are represented on all project teams,
cores teams and inter-project collaborations, so that they can bring their unique and important perspective to help meet the
patient-centric mandate of I-SPY2.2.
Specific Aim 1: Organize, integrate, and provide administrative management of all Projects and Core
Specific Aim 2: Provide project management oversight to track milestones and timelines of the individual Projects and
Cores.
Specific Aim 3: Facilitate collaborations and disseminate information
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Enhancing the Diversity of Participants in the WISDOM Clinical Trial: Practical Challenges and Ethical Implications
-
批准号:10367828
-
项目类别:
-
资助金额:$16.15万
-
财政年份:2020
-
负责人:LAURA J ESSERMAN
-
依托单位:
Surgical Oncology Training Grant
-
批准号:10434765
-
项目类别:
-
资助金额:$30.37万
-
财政年份:2020
-
负责人:LAURA J ESSERMAN
-
依托单位:
Surgical Oncology Training Grant
-
批准号:10683105
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2020
-
负责人:LAURA J ESSERMAN
-
依托单位:
Extending the Diversity, Reach, and Generalizability of the WISDOM Study
-
批准号:10368970
-
项目类别:
-
资助金额:$186.14万
-
财政年份:2020
-
负责人:LAURA J ESSERMAN
-
依托单位:
Extending the Diversity, Reach, and Generalizability of the WISDOM Study
-
批准号:10593908
-
项目类别:
-
资助金额:$181.76万
-
财政年份:2020
-
负责人:LAURA J ESSERMAN
-
依托单位:
Surgical Oncology Training Grant
-
批准号:10216206
-
项目类别:
-
资助金额:$33.14万
-
财政年份:2020
-
负责人:LAURA J ESSERMAN
-
依托单位:
Extending the Diversity, Reach, and Generalizability of the WISDOM Study
-
批准号:9888251
-
项目类别:
-
资助金额:$150.84万
-
财政年份:2020
-
负责人:LAURA J ESSERMAN
-
依托单位:
Surgical Oncology Training Grant
-
批准号:10025197
-
项目类别:
-
资助金额:$16.09万
-
财政年份:2020
-
负责人:LAURA J ESSERMAN
-
依托单位:
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
-
批准号:9789198
-
项目类别:
-
资助金额:$195.45万
-
财政年份:2017
-
负责人:LAURA J ESSERMAN
-
依托单位:
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
-
批准号:10013133
-
项目类别:
-
资助金额:$184.54万
-
财政年份:2017
-
负责人:LAURA J ESSERMAN
-
依托单位:
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes
-
批准号:10628608
-
项目类别:
-
资助金额:$268.95万
-
财政年份:2017
-
负责人:LAURA J ESSERMAN
-
依托单位:
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
-
批准号:9360068
-
项目类别:
-
资助金额:$233.95万
-
财政年份:2017
-
负责人:LAURA J ESSERMAN
-
依托单位:
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
-
批准号:10249153
-
项目类别:
-
资助金额:$180.08万
-
财政年份:2017
-
负责人:LAURA J ESSERMAN
-
依托单位:
Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancers
-
批准号:9337415
-
项目类别:
-
资助金额:$78.25万
-
财政年份:2015
-
负责人:LAURA J ESSERMAN
-
依托单位:
Integrated Biomarkers to Characterize Breast Cancer Risk
-
批准号:7121540
-
项目类别:
-
资助金额:$81.22万
-
财政年份:2004
-
负责人:LAURA J ESSERMAN
-
依托单位:
Integrated Biomarkers to Characterize Breast Cancer Risk
-
批准号:6847727
-
项目类别:
-
资助金额:$70.0万
-
财政年份:2004
-
负责人:LAURA J ESSERMAN
-
依托单位:
Integrated Biomarkers to Characterize Breast Cancer Risk
-
批准号:7908599
-
项目类别:
-
资助金额:$55.51万
-
财政年份:2004
-
负责人:LAURA J ESSERMAN
-
依托单位:
Integrated Biomarkers to Characterize Breast Cancer Risk
-
批准号:6950841
-
项目类别:
-
资助金额:$79.64万
-
财政年份:2004
-
负责人:LAURA J ESSERMAN
-
依托单位:
Integrated Biomarkers to Characterize Breast Cancer Risk
-
批准号:7487841
-
项目类别:
-
资助金额:$75.7万
-
财政年份:2004
-
负责人:LAURA J ESSERMAN
-
依托单位:
Integrated Biomarkers to Characterize Breast Cancer Risk
-
批准号:7282352
-
项目类别:
-
资助金额:$75.37万
-
财政年份:2004
-
负责人:LAURA J ESSERMAN
-
依托单位:
海外基金